» Articles » PMID: 31161036

Epidemiology, Species Distribution, Antifungal Susceptibility and Mortality Risk Factors of Candidemia Among Critically Ill Patients: a Retrospective Study from 2011 to 2017 in a Teaching Hospital in China

Overview
Publisher Biomed Central
Date 2019 Jun 5
PMID 31161036
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Candidemia is still a common life-threatening disease and causes significant morbidity and mortality, especially in critically ill patients. We conducted this study to analyze the epidemiology, clinical characteristics, species distribution, antifungal susceptibility and mortality risk factors of candidemia in an intensive care unit.

Methods: We retrospectively analyzed patients with candidemia in the intensive care unit of our hospital from 2011 to 2017. The clinical characteristics, including clinical and laboratory data, antibiotic therapies, underlying conditions, and invasive procedures and outcomes, were analyzed. We also performed a logistic regression analysis to identify the independent risk factors for mortality.

Results: In this six-year retrospective study, we identified 82 patients with candidemia. The median age of the patients was 76 years (range, 26 years to 91 years), and 50 of the patients (61%) were male. was the most common fungal species (38/82, 46.3%), followed by (16/82, 19.5%), (13/82, 15.9%), and (12/82, 14.6%). Most isolates were susceptible to the antifungal agents. The all-cause mortality rate was 51.2%. In binary logistic regression analysis, the worst Glasgow coma score (GCS), PaO/FiO ratio (P/F ratio), and mean arterial pressure (MAP) within three days after admission were independent risk factors for mortality.

Conclusions: was the most frequently isolated fungal species. Most isolates were susceptible to the antifungal agents. The worst GCS score, P/F ratio, and MAP within three days after admission were independent risk factors for mortality due to candidemia in critically ill patients.

Citing Articles

Nineteen years retrospective analysis of epidemiology, antifungal resistance and a nomogram model for 30-day mortality in nosocomial candidemia patients.

Dai Z, Lan X, Cai M, Liao Y, Zhang J, Ye N Front Cell Infect Microbiol. 2025; 15:1504866.

PMID: 39963405 PMC: 11830704. DOI: 10.3389/fcimb.2025.1504866.


Candidemia chronicles: Retrospective analysis of candidemia epidemiology, species distribution, and antifungal susceptibility patterns in Bahrain.

Saeed N, Almusawi S, Al-Beltagi M World J Virol. 2024; 13(4):98839.

PMID: 39722764 PMC: 11551684. DOI: 10.5501/wjv.v13.i4.98839.


Antifungal Susceptibility Data and Epidemiological Distribution of spp.: An In Vitro Five-Year Evaluation at University Hospital Policlinico of Catania and a Comprehensive Literature Review.

Calvo M, Scalia G, Trovato L Antibiotics (Basel). 2024; 13(10).

PMID: 39452181 PMC: 11505318. DOI: 10.3390/antibiotics13100914.


Chemical composition and antimicrobial activity of a newly identified chemotype of Achillea wilhelmsii K.Koch from Kashan, Iran.

Ghavam M, Castangia I, Manconi M, Bacchetta G, Manca M Sci Rep. 2024; 14(1):22655.

PMID: 39349567 PMC: 11443101. DOI: 10.1038/s41598-024-73284-0.


Phenotypic and Genotypic Characterization of Resistance and Virulence Markers in spp. Isolated from Community-Acquired Infections in Bucharest, and the Impact of AgNPs on the Highly Resistant Isolates.

Corbu V, Georgescu A, Marinas I, Pericleanu R, Mogos D, Dumbrava A J Fungi (Basel). 2024; 10(8).

PMID: 39194889 PMC: 11355189. DOI: 10.3390/jof10080563.


References
1.
Arendrup M, Dzajic E, Jensen R, Johansen H, Kjaeldgaard P, Knudsen J . Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect. 2013; 19(8):E343-53. DOI: 10.1111/1469-0691.12212. View

2.
Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J . Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis. 2004; 38(3):311-20. DOI: 10.1086/380637. View

3.
Martin-Loeches I, Perner A . Focus on infection and sepsis in intensive care patients. Intensive Care Med. 2016; 42(4):491-493. DOI: 10.1007/s00134-016-4234-6. View

4.
Liu W, Lai C, Li M, Wu C, Ko W, Hung Y . Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014. J Microbiol Immunol Infect. 2017; 52(4):612-619. DOI: 10.1016/j.jmii.2017.08.007. View

5.
Pappas P, Kauffman C, Andes D, Clancy C, Marr K, Ostrosky-Zeichner L . Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2015; 62(4):e1-50. PMC: 4725385. DOI: 10.1093/cid/civ933. View